KR20240112343A - 무스카린성 아세틸콜린 수용체 m4의 길항제 - Google Patents
무스카린성 아세틸콜린 수용체 m4의 길항제 Download PDFInfo
- Publication number
- KR20240112343A KR20240112343A KR1020247021498A KR20247021498A KR20240112343A KR 20240112343 A KR20240112343 A KR 20240112343A KR 1020247021498 A KR1020247021498 A KR 1020247021498A KR 20247021498 A KR20247021498 A KR 20247021498A KR 20240112343 A KR20240112343 A KR 20240112343A
- Authority
- KR
- South Korea
- Prior art keywords
- compound
- pharmaceutically acceptable
- acceptable salt
- alkyl
- cycloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163284750P | 2021-12-01 | 2021-12-01 | |
| US63/284,750 | 2021-12-01 | ||
| PCT/US2022/051493 WO2023102100A1 (en) | 2021-12-01 | 2022-12-01 | Antagonists of the muscarinic acetylcholine receptor m4 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20240112343A true KR20240112343A (ko) | 2024-07-18 |
Family
ID=84943708
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020247021498A Pending KR20240112343A (ko) | 2021-12-01 | 2022-12-01 | 무스카린성 아세틸콜린 수용체 m4의 길항제 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250145595A1 (https=) |
| EP (1) | EP4441046A1 (https=) |
| JP (1) | JP2024543973A (https=) |
| KR (1) | KR20240112343A (https=) |
| CN (2) | CN116669737A (https=) |
| AU (1) | AU2022400780A1 (https=) |
| CA (1) | CA3241298A1 (https=) |
| IL (1) | IL313219A (https=) |
| MX (1) | MX2024006718A (https=) |
| WO (1) | WO2023102100A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2018300980A1 (en) | 2017-07-12 | 2020-01-02 | Vanderbilt University | Antagonists of the muscarinic acetylcholine receptor M4 |
| IL273924B2 (en) | 2017-10-20 | 2024-07-01 | Univ Vanderbilt | Antagonists of the muscarinic acetylcholine receptor m4 |
| CA3155864A1 (en) | 2019-10-04 | 2021-04-08 | Vanderbilt University | Antagonists of the muscarinic acetylcholine receptor m4 |
| EP4491228A3 (en) * | 2020-12-22 | 2025-04-23 | Vanderbilt University | Antagonists of the muscarinic acetylcholine receptor m4 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112018003417B1 (pt) * | 2016-06-22 | 2023-10-24 | Vanderbilt University | Composto modulador alostérico positivo do receptor muscarínico de acetilcolina m4 e composição farmacêutica que o compreende |
| JP2020530451A (ja) * | 2017-08-08 | 2020-10-22 | ヴァンダービルト ユニバーシティー | ムスカリン性アセチルコリン受容体ｍ４のアンタゴニスト |
| IL273924B2 (en) * | 2017-10-20 | 2024-07-01 | Univ Vanderbilt | Antagonists of the muscarinic acetylcholine receptor m4 |
| WO2021119254A1 (en) * | 2019-12-10 | 2021-06-17 | Vanderbilt University | Antagonists of the muscarinic acetylcholine receptor m4 |
| US20230183218A1 (en) * | 2020-04-24 | 2023-06-15 | Vanderbilt University | Condensed substituted hydropyrroles as antagonists of the muscarinic acetylcholine receptor m4 |
| EP4139303A1 (en) * | 2020-04-24 | 2023-03-01 | Vanderbilt University | Condensed substituted hydropyrroles as antagonists of the muscarinic acetylcholine receptor m4 |
-
2021
- 2021-12-22 CN CN202180087480.8A patent/CN116669737A/zh active Pending
-
2022
- 2022-12-01 AU AU2022400780A patent/AU2022400780A1/en active Pending
- 2022-12-01 EP EP22843543.4A patent/EP4441046A1/en active Pending
- 2022-12-01 CA CA3241298A patent/CA3241298A1/en active Pending
- 2022-12-01 JP JP2024532491A patent/JP2024543973A/ja active Pending
- 2022-12-01 KR KR1020247021498A patent/KR20240112343A/ko active Pending
- 2022-12-01 IL IL313219A patent/IL313219A/en unknown
- 2022-12-01 US US18/715,048 patent/US20250145595A1/en active Pending
- 2022-12-01 MX MX2024006718A patent/MX2024006718A/es unknown
- 2022-12-01 WO PCT/US2022/051493 patent/WO2023102100A1/en not_active Ceased
- 2022-12-01 CN CN202280088712.6A patent/CN118541365A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2022400780A1 (en) | 2024-06-20 |
| CN118541365A (zh) | 2024-08-23 |
| MX2024006718A (es) | 2024-08-09 |
| JP2024543973A (ja) | 2024-11-26 |
| EP4441046A1 (en) | 2024-10-09 |
| CA3241298A1 (en) | 2023-06-08 |
| IL313219A (en) | 2024-07-01 |
| US20250145595A1 (en) | 2025-05-08 |
| CN116669737A (zh) | 2023-08-29 |
| WO2023102100A1 (en) | 2023-06-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102776114B1 (ko) | 무스카린성 아세틸콜린 수용체 m4의 길항제 | |
| EP4267569B1 (en) | Antagonists of the muscarinic acetylcholine receptor m4 | |
| EP4037677B1 (en) | Antagonists of the muscarinic acetylcholine receptor m4 | |
| KR20240112343A (ko) | 무스카린성 아세틸콜린 수용체 m4의 길항제 | |
| CA3163933A1 (en) | Antagonists of the muscarinic acetylcholine receptor m4 | |
| WO2021216951A1 (en) | Condensed substituted hydropyrroles as antagonists of the muscarinic acetylcholine receptor m4 | |
| JP2023522959A (ja) | ムスカリンアセチルコリン受容体ｍ４のアンタゴニストとしての縮合置換ヒドロピロール | |
| EP4247803A1 (en) | Antagonists of the muscarinic acetylcholine receptor m4 | |
| JP2023506741A (ja) | ムスカリン性アセチルコリン受容体ｍ４のアンタゴニスト | |
| WO2022212819A1 (en) | Indazole derivatives as antagonists of the muscarinic acetylcholine receptor m4 | |
| WO2022261427A1 (en) | (4-(6-((2-octahydrocyclopenta[c]pyrrol-5-yl)amino)pyridazin-3-yl)phenyl)(imino)(methyl)-lambda6- sulfanone derivatives and similar compounds as muscarinic acetylcholine receptor m4 antagonists for the treatment of neurodegenerative disorders | |
| WO2022036177A1 (en) | Antagonists of the muscarinic acetylcholine receptor m4 | |
| HK40121280A (en) | Antagonists of the muscarinic acetylcholine receptor m4 | |
| HK40097532A (zh) | 毒蕈碱型乙酰胆碱受体m4的拮抗剂 | |
| HK40115503A (zh) | 毒蕈硷型乙醯胆硷受体m4的拮抗剂 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| E13 | Pre-grant limitation requested |
Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |